NVO Stock Price Today (September 2026) — Novo Nordisk A/S Analysis & Key Metrics 2026-09-04
Novo Nordisk A/S (NVO) is trading at $46.60, down 1.92% today (as of September 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $47.17 (1.2% upside).
- Volatility remains elevated (27.58% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.10% YoY) alongside significant competitive pressures.
NVO Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Novo Nordisk A/S - Historical Price & Volume
Market Cap
Enterprise Value: $297.11B
P/E Ratio
Forward P/E: 13.29
Revenue Growth
Year over Year
Analyst Target
+1.2% upside potential
Key Investor Questions About NVO
What investors need to know before buying
Based on current market data, NVO presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 50.95)
- Fundamentals say: Caution warranted (high leverage concerns)
NVO's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NVO investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $140.13B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, NVO stock traded between $35.12 and $64.16—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 27.58% annualized volatility and β=0.97, the stock exhibits moderate correlation to market moves—making NVO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other.
Eli Lilly is worth 5.5x Novo Nordisk but earns nowhere near 5.5x more. Here's how the obesity pill war, a 13x vs. 32x valuation gap, and the dividend stack up, and which one I'd buy.
Wegovy’s Latest Trial Gives Novo Nordisk (NVO) Another Potential Growth Catalyst
Novo Nordisk A/S (NYSE:NVO) has delivered encouraging late-stage data for Wegovy in younger children, with its STEP Young trial showing that 40.4% of children aged 6 to under 12 were no longer classified as having obesity after 68 weeks of semaglutide treatment, compared with none in the placebo group. The trial met its primary endpoint, […]
Novo is Down Nearly 2% as a 40.4% Childhood Win Meets Two Trial Cancellations
A pediatric obesity success collided with another cardiovascular retreat, leaving Novo's concentration problem unresolved.
Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.
Weight loss is just the beginning of GLP-1's: Novo Nordisk CEO
Yahoo Finance Executive Editor Brian Sozzi chats with Novo Nordisk CEO Mike Doustdar about the true timeline for how GLP-1s will impact the food and airline industries, and what the future of weight loss and preventative health looks like over the next decade.
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
Novo Nordisk (CPSE:NOVO B) Stock Looks Below Fair Value But Faces Earnings Doubts
Novo Nordisk stock has fallen sharply over the past three years, yet valuation checks still lean toward the shares looking cheap rather than stretched. With fresh questions around obesity drug competition, patent risk and a changing leadership team, investors are weighing whether that discount is a warning sign or an opportunity. The share price has declined 51.9% over the past three years, which puts a clear spotlight on whether the current level already reflects the main concerns around...
Sector Update: Healthcare Stocks Decline Friday Afternoon
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H
Novo Nordisk Falls 2% as Wegovy Opens a German Front
Germany is the first EU pill market, but pen-equivalent pricing means convenience--not discounting--must win adoption.
Explore More Analysis for NVO
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Novo Nordisk A/S
Novo Nordisk A/S (NVO) is currently trading at $46.60. The RSI (14-day) is at 51.0, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $47.17 implies 1.2% upside from current levels. Volatility is moderate at 27.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Novo Nordisk A/S (NVO): The trailing P/E ratio is 11.39, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 13.29. The PEG ratio is 3.14, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 5.98. Price-to-Sales is 0.47. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering NVO, the consensus price target is $47.17. This represents a 1.2% upside from the current price of $46.60. The range spans from a low target of $40.21 to a high target of $64.07, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Novo Nordisk A/S (NVO) pays a dividend with a current yield of approximately 3.86%. The annualized dividend rate is $11.70 per share. The payout ratio is 44.5%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-08-17T00:00:00.000Z.
Key risks for Novo Nordisk A/S (NVO) investors include: 1. Moderate volatility (27.6% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Novo Nordisk A/S's (NVO) current debt and financial health profile: Total debt stands at $140.13B. The debt-to-equity ratio is 63.33, which is moderate and generally manageable for most companies. The current ratio is 0.87, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.64. The company holds $44.98B in cash and equivalents. Free cash flow is positive at $37.67B, providing a cushion for debt servicing and shareholder returns.